AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating ...

UK medtech company Brainomix has been granted FDA approval for a new feature for its artificial intelligence-powered stroke ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

AbbVie has won expanded European approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with giant cell arteritis.

Goldman Sachs analyst Asad Haider assumed coverage of AbbVie (ABBV) with a Neutral rating and $194 price target The company’s “strong” growth ...

AbbVie today announced that the European Commission (EC) granted marketing authorization to RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in adult patients.

AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading ...

Tremfya achieved an impressions share of voice (SOV) of 3.35%, generating 2.1 billion total impressions. While the brand held the top spot, the total impressions dipped by 2 million from when Sanofi ...

In this wide and deep sector, though, there are some notable exceptions. Let's take a look at two outliers with dividend policies that have looked especially attractive lately -- pharmaceutical ...

Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...

C disinfection cabinet market with its SaniUV-Cubetm, designed to quickly neutralize bacteria, mold, and viruses on many small items. It is constructed from stainless steel for extreme ...

AbbVie’s stock is having a glow-up, climbing 16.1% in 2025, leaving the industry and S&P 500 behind in the dust. The company deftly pivoted after Humira’s fall from patent grace by betting big on ...